Drug Type NK cell engagers (NKCE) |
Synonyms CD33 NKE, CD33-NKE |
Target |
Action inhibitors |
Mechanism CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Relapse multiple myeloma | Phase 1 | United States | 30 Jan 2022 | |
| Multiple Myeloma | Phase 1 | United States | 30 Jan 2021 |






